Association Between Eosinophilic Esophagitis, Atopic Disease, and IBD in Children
Research presented at ACAAI 2021 assessed associations between IBD, eosinophilic esophagitis, esophageal eosinophilia, and atopic disease in children.
Eosinophilic Esophagitis
Tezepelumab Granted Orphan Drug Status for Eosinophilic Esophagitis
Tezepelumab is a first-in-class human monoclonal antibody that works by blocking thymic stromal lymphopoietin.
Dupilumab Could Be Promising Treatment for Eosinophilic Esophagitis: Q&A
Weekly dupilumab improved disease-specific health-related quality of life and symptom burden in adolescent and adult patients with eosinophilic esophagitis.
Budesonide Oral Suspension Improves Multiple Outcomes in Pediatric Eosinophilic Esophagitis
Budesonide oral suspension improved histologic, endoscopic, and both histologic and symptomatic outcomes in children with eosinophilic esophagitis compared with placebo.
Increased Risk of Eosinophilic Esophagitis in Children With IBD
Researchers evaluated the potential predictive characteristics of eosinophilic esophagitis following IBD diagnosis in children.
Active Eosinophilic Esophagitis Associated With Increased Asthma Severity
Active eosinophilic esophagitis appears to be associated with lower lung function and increased asthma severity in children with comorbid asthma.
Novel Budesonide Oral Suspension Gets Priority Review for Eosinophilic Esophagitis
The FDA has accepted for review the NDA and granted Priority Review to TAK-721 (budesonide oral suspension) for the treatment of eosinophilic esophagitis.
Dupilumab Gets Breakthrough Therapy Status for Eosinophilic Esophagitis
The designation was based on results from Part A of a double-blind, placebo-controlled, pivotal phase 3 trial.
Clinical, Anatomic Improvements With Dupilumab in Eosinophilic Esophagitis Study
Dupilumab was associated with clinical and anatomic improvements in patients with eosinophilic esophagitis, according to results from a pivotal phase 3 study.
Long-Term Eosinophilic Esophagitis Successfully Treated With JAK Inhibitor
Several treatments were attempted but failed to manage the patient’s conditions, including proton pump inhibitors, topical steroids, a restricted diet, and infliximab (3 doses) for arthritis.
- Loading...
Loading...
Next post in Allergies
Loading... 
Loading...